Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

April 20, 2016April 20, 2016

Immune System Compounds, Alpha Defensins, Seen to Reduce Inflammation Linked to Arthritis

News

Compounds produced by the immune system can help reduce inflammation and prevent damage to healthy tissues, a finding with important implications in the treatment of conditions like rheumatoid arthritis (RA) and sepsis. The study, ... Read more

April 15, 2016April 15, 2016

Smoking Linked to 2x Higher Risk of Premature Death in Rheumatoid Arthritis Patients

News

Smoking is associated with earlier death in people with rheumatoid arthritis, a correlation that significantly decreased upon smoking cessation, according to a study led by University of Manchester researchers. The article, “Smoking-related mortality in patients ... Read more

April 11, 2016April 11, 2016

Phase 3 Trial Shows Rheumatoid Arthritis Symptoms Significantly Improved with Baricitinib

News

Eli Lilly and Incyte Corporation recently announced novel data from the pivotal Phase 3 RA-BEACON global trial of baricitinib, a once-daily oral drug presently under regulatory review for moderate-to-severe rheumatoid arthritis (RA). ... Read more

April 1, 2016April 1, 2016

Pfizer’s MAA for Rheumatoid Arthritis Treatment Xeljanz to Be Reviewed by European Medicines Agency

News

The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application for Pfizer’s Xeljanz (5 mg tablets twice daily) to treat adults with moderate to severely active rheumatoid arthritis in ... Read more

March 30, 2016March 30, 2016

Mesoblast’s Cell-Based Treatment of Rheumatoid Arthritis Granted US Patent

News

The U.S. Patent and Trademark Office has granted a key patent covering the use of Mesoblast Limited’s Mesenchymal Precursor Cells (MPCs) for the prevention or treatment of rheumatoid arthritis (RA) and ... Read more

March 28, 2016March 28, 2016

Rheumatoid Arthritis Drug, Vimovo Delayed-Release Tablets, Approved for US Patent

News

Horizon Pharma has received a Notice of Allowance from the U.S. Patent and Trademark Office for its application covering Vimovo tablets, a fixed-dose combination of delayed-release enteric-coated naproxen (a non-steroidal anti-inflammatory drug, or NSAID), and immediate-release ... Read more

March 23, 2016March 23, 2016

Higher Risk of Developing Rheumatoid Arthritis Discovered in Women with PTSD, According to Study

News

Women with post-traumatic stress disorder are at increased risk to developing rheumatoid arthritis, whether or not they smoke, according to a study recently published in the journal Arthritis Care & Research. Post-traumatic ... Read more

March 14, 2016March 14, 2016

Phase 3 Trial Results Look Promising for Rheumatoid Arthritis Treatment Sarilumab

News

Sanofi and Regeneron Pharmaceuticals recently announced their Phase 3 clinical trial met its primary endpoint: Sarilumab was superior to adalimumab (Humira) at Week 24 in improving signs and symptoms in 369 ... Read more

March 11, 2016March 11, 2016

Weight Gain, Loss in Rheumatoid Arthritis Patients Influenced by Disease-Modifying Drugs

News

Of four disease-modifying antirheumatic drugs for patients with rheumatoid arthritis, leflunomide was most likely to cause weight loss and prednisone was most associated with weight gain, results of a study indicate. The ... Read more

March 7, 2016March 7, 2016

Rheumatoid Arthritis Successfully Treated with a Green Tea Compound in Animal Study

News

Scientists have identified a compound in green tea that could be used to treat the joint pain, inflammation, and tissue damage caused by rheumatoid arthritis (RA). Their study, “Regulation of Transforming Growth Factor ... Read more